Business
SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67%
DALLAS & LYON, France, January 20, 2026--Regulatory News: SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA, eligible for the PEA-PME scheme), a French-American player specialized in complex spine surgery, offering an integrated pre, intra, and post-operative solution based on a 3D planning software, adaptive implants and related services, today published its annual sales and cash position for the full year to December 31,
About this update from S.m.a.i.o S.a.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":377,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/d3689c7bb172e2b3436b926a119dd82e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1jjUdy9Tq1c.7UnnZtKUFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg5ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d3689c7bb172e2b3436b926a119dd82e","width":377,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. sales rose by +138% to €7m, and by +160% to $7.9m (excluding currency effects).","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":84,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong growth across North American centers that were already active in 2024 (+130%).","length":85,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":85,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"11 new North American surgeons using SMAIO solutions in 2025, representing less than 10% of total sales, suggesting continued sustained growth in 2026.","length":151,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":151,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Two major initial industrial partnerships signed in 2025 for the KEOPS-4ME open platform, enabling the large-scale rollout of patient-specific K-Rods starting in Q2 2026.","length":170,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":170,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong cash position of €5.8m as of December 31, 2025.","length":54,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":54,"olType":false},{"type":"text","content":"Webconference in French today at 6:30 pm CET:REGISTER HERE","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"DALLAS & LYON, France, January 20, 2026--(BUSINESS WIRE)--Regulatory News:","length":78,"tagName":"p"},{"type":"text","content":"SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA, eligible for the PEA-PME scheme), a French-American player specialized in complex spine surgery, offer...